SVRA - Company ID 0001160308
Savara Inc trades as SVRA and has a market capitalization of $1.24 B, making it the #2499 largest US-listed company by market value. This page tracks Savara Inc through 1,329 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 10 fiscal years Savara Inc's revenue declined from $488.96K to $257.00K, a compound annual decline rate of 6.2%.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
| PRE 14A | - | 2026-04-10 |
| Insider trade | 4 | 2026-03-20 |
| Major company event | 8-K | 2026-03-13 |
| Annual report | 10-K | 2026-03-13 |
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY.
**\-\- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 --**
_Achieved Regulatory Milestones for the MOLBREEVI\* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP):_ - _Biologics License Application (BLA) Filed by the U.S. Food & Drug Administration (FDA), Prescription Drug User Fee Act (PDUFA) Target Action Date is November 22, 2026_
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters.
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
The largest companies sharing Savara Inc's SEC industry classification (pharmaceutical preparations).
Savara Inc (SVRA) has a market capitalization of $1.24 B as of 2026-07-10, ranking #2499 among US-listed companies.
In its latest fiscal year Savara Inc reported a net loss of $118.84M.